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New vectors, new approaches, new disease targets and the first EU licence for 
a gene therapy have injected a much-needed dose of fresh hope into this field. 
Investment is flowing and further therapies are expected to follow. Michael Gross
New hopes for gene therapyreports.Hopes were running high at the 
end of the 20th century. The newly 
hatched internet economy took off, the 
Cold War was consigned to history, 
two separate teams were racing to 
sequence the human genome, and 
once that was in the databanks, 
surely we would understand much 
more about our diseases and develop 
new cures based on the genetic 
insights. And Al Gore might become 
US president and do something about 
climate change. 
Fifteen years on, humanity has 
achieved very little of what we may 
have reasonably hoped for at the 
approach of the millennium. Genomics 
has delivered unprecedented insights 
into evolution and functional biology, 
but fallen short on the headline goal of 
addressing common medical problems 
like cancer and heart disease. The 
idea of repairing defective genes 
causing diseases suffered even more 
disappointment. 
In  September 1999, Jesse Gelsinger, 
an 18-year-old patient with ornithine 
transcarbamylase deficiency taking 
part in a clinical trial for a gene 
therapy treatment, died after a severe 
immune response to the adenovirus Human helix: High hopes were placed on the 
early setbacks. (Photo: Courtesy of Genentechvector used to smuggle the repair 
genes into his liver cells. Further 
setbacks followed when other patients 
developed cancers blamed on the 
treatment. Thus, as the human genome
reached completion, the project of 
repairing genomes had to go back to 
the drawing board and come back with
new methods. 
More than a decade later, gene 
therapy is now returning to the 
spotlight with safer methods, a wider 
range of target diseases, and a 
growing number of successful clinical 
trials. In November 2012, the EU’s 
licensing of the Glybera gene therapy 
developed by the company uniQure 
signalled the definitive comeback of 
the idea. The wide range of therapies 
now in development and in clinical 
trials seems to suggest that many more
will follow.  
New vectors
The death of Jesse Gelsinger, as 
well as the subsequent cases of 
cancers resulting from treatment, 
were all blamed on the vectors 
used. Adenovirus can trigger an 
immune response, and retroviruses 
can incorporate themselves at rapid advances in molecular biology, but clinic
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unsuitable locations activating tumour 
development. 
Since then, adeno-associated virus 
(AAV) has become the preferred choice 
of viral vector, as it causes no known 
side-effects and only a very mild 
immune response. The only problem 
so far identified with this benign human 
virus is that it is fairly widespread, 
to the extent that many patients will 
already have immunity against some 
strains of the virus. Researchers can 
sidestep this problem by choosing 
a rare strain of the virus, or by using 
it in the brain where the neutralising 
antibodies don’t patrol, but for wider 
clinical applications it remains a 
limitation. 
The first licensed gene therapy 
treatment, uniQure’s Glybera, uses 
a vector derived from AAV serotype 
1. It treats a rare inherited disease, 
lipoprotein lipase (LPL) deficiency, 
where the absence of a fat-digesting 
enzyme leads to inflammation of 
the pancreas. Injection of the vector 
carrying the LPL gene enables 
expression of the enzyme in muscles. 
Many other treatments using 
AAV-based vectors are currently 
undergoing or have recently completed 
clinical trials, including therapies 
for hemophilia, cystic fibrosis, and 
age-related macular degeneration. 
However, there is still a case for 
developing alternative, non-viral 
 al applications of gene therapy were delayed by 
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Perfect packaging: A key issue in gene therapy is the choice of the vector used to introduce 
genetic material into cells. As an alternative to the viruses currently used, polymer nanoparti-
cles have shown some promise. (Image: With permission from from J.C. Sunshine, C.J. Bishop, 
J.J. Green. (2011). Therapeutic Delivery 2, 493–521.)delivery vectors, and there is a wide 
range of chemical approaches that 
could be applied to this task. 
As DNA carries negative charges 
by default, it readily self-assembles 
with cationic polymers, which can be 
used for the formation of nanoparticles 
carrying the gene of interest. The group 
of Jordan Green at Johns Hopkins 
University in Baltimore, Maryland, USA, 
has developed a polymer library based 
on a family of cationic linear polymers, 
the poly -aminoesters. As with natural 
peptides and proteins, a variety of 
sidechains can equip these polymers 
with a wide range of chemical 
properties and structures. 
Green’s lab has shown that 
these polymers self-assemble and 
encapsulate up to 100 plasmids in each 
nanoparticle. The resulting particles 
are non-toxic and biodegradable, with 
half-lives in the range of a few hours. In 
a study directed at applications against 
human brain cancers, the researchers 
found that the nanoparticles have an 
intrinsic preference to incorporate 
themselves into primary cancer cells 
rather than into the neural progenitor 
cells, removing the need for specific 
targeting ligands (ACS Nano (2014) 8, 
5141–5153).
Other types of molecules, 
including lipids, peptides, sugars and dendrimers (polymers with branching 
rather than linear connectivity), 
are also being investigated for the 
development of new vectors for gene 
therapy. Dendrimers, for instance, are 
discussed as a promising option for 
eye diseases (J. Pharm. Pharmacol. 
(2013) 66, 542–556). 
Finally, some researchers have 
combined the molecular design 
approach with the idea of using viral 
vectors by building novel, virus-
like shells from scratch. The group 
of Renko de Vries at Wageningen 
University, Netherlands, used the 
cylindrical shell of tobacco mosaic 
virus, a much-studied example of 
natural protein self-assembly, as a 
model to build an entirely new DNA-
coating shell from three simple protein 
building blocks (Nat. Nanotechnol. 
(2014) DOI: 10.1038/nnano.2014.169). 
A sequence of lysine residues provides 
the cationic sites that bind the DNA. 
This is followed by a sequence gleaned 
from natural silk, providing structural 
stability with a high percentage of 
alanine and glycine. By varying the 
number of these silk-like repeats, the 
researchers could fine-tune the self-
assembly process. The third part of the 
sequence, displayed on the outside 
of the virus-like rod, can be freely 
manipulated to guide the behaviour of the rods in suspension, e.g. stop them 
from aggregating. 
So far, this recent work has focused 
on the self-assembly process itself and
the packaging of DNA, but it could be 
easily developed into new vectors for 
gene therapy. In a similar approach, 
Kenneth Woycechowsky’s group at 
the University of Utah at Salt Lake 
City, USA, has mutated a non-viral 
protein to enable it to form virus-like 
capsid structures (J. Am. Chem. Soc. 
(2012) 134, 13152–13155). The idea is 
to take the benefit of viral packaging 
and delivery mechanisms without the 
disadvantage of recognition by the 
immune system. 
New approaches
The first gene therapy projects typically
involved providing a spare copy of the 
defective gene. Recent progress has 
added other possibilities, including 
editing genes, silencing them, and 
introducing toxic genes to specifically 
kill cancer cells. 
One promising approach to gene 
editing is the CRISPR/Cas9 system, 
which evolved in bacteria as a kind 
of adaptive immune system against 
phages. The editing technique 
derived from it involves targeting an 
endonuclease, Cas9, directed by a guide
RNA, to a specific site in the genome 
where it creates a double-strand break. 
The versatility of the technique relies 
on the fact that the guide RNA can be 
designed to target virtually any site in 
any known genome. If desired, Cas9 
can also be combined with different 
guide RNAs to target several sites at 
once. The break can then be repaired 
either non-homologously, resulting in an
insertion or deletion, or in a template-
directed way. 
The group of Eric Olson at the 
University of Texas Southwestern 
Medical Center at Dallas, USA,  has 
recently demonstrated that editing 
of germline DNA in a mouse model 
of muscular dystrophy can repair 
the gene defect and result in healthy 
mice (Science (2014) 345, 1184–1188). 
Intriguingly, the authors found that 
it is not necessary to have the 
corrected gene present in all cells. 
The experiments produced a range of 
mosaicism, with the corrected version 
present in between 2% and 100% 
of the cells of a given animal. The 
success of the cure at the phenotype 
level consistently surpassed the 
percentage of repaired cells, 
suggesting that corrected cells have 
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Cool science: Amyotrophic lateral sclerosis (ALS), the neuromuscular disorder made famous 
by the viral spread of the ice-bucket challenge, is among the neuromuscular disorders that 
could potentially be treated with gene therapy. (Photo: Gail Teitzel.)a beneficial influence in muscle fibre 
organisation beyond what would be 
expected from their number. 
Earlier this year, the group of 
Daniel Anderson at MIT reported 
the application of CRISPR/Cas9 
gene repair to mice with an enzyme 
deficiency, achieved by injecting Cas9,
guide RNA and the repair template into
a vein. They found that 0.4% of liver 
cells in the treated animals carried out 
the desired repair successfully and, 
again, regain of function exceeded 
the percentage of repaired cells (Nat. 
Biotechnol. (2014) 32, 551–553).
“Genomic editing to cure diseases 
caused by single gene mutations, as 
shown in our recent study of Duchenne
muscular dystrophy, represents a 
powerful approach to eliminate disease
causing genetic lesions and allow for 
permanent restoration of normal cellula
function,” Olson explained. He showed 
himself optimistic that the approach wil
become medically useful: “While there 
will be hurdles, such as scale up and 
efficiency of cellular delivery of gene 
editing components, I believe these can
be overcome in the very near future,” he
concluded.
Genome editing in the human 
germline is not feasible at the moment
and would raise ethical questions 
if it became possible. However, the 
observation that muscle function 
can be rescued with only a small 
percentage of repaired cells also open
up the possibility of applying gene 
therapy for muscular dystrophy at the 
somatic level. 
Another new approach that has 
broadened the concept of gene 
therapy is the introduction of genes 
with the intention to kill cells. For 
instance, if genes triggering apoptosis
could be targeted specifically at 
cancer cells, and more importantly, at 
the progenitor cells from which new 
tumours will grow, this could be a 
breakthrough in cancer treatment. 
For example, one of the diseases tha
Jordan Green’s group hopes to fight 
with the novel polymer nanoparticles 
mentioned above is glioblastoma, 
which is both the most common kind 
of primary brain tumour in adults and 
the most deadly one. In spite of all the 
surgery, radiation and chemotherapy 
that modern medicine has thrown at 
this problem, half of the patients die 
within 15 months of diagnosis. 
Typically, surgical removal of the 
tumour leaves behind brain tumour 
initiating cells (BTICs), which may  
 
 
s 
 
t 
lead to a recurrence of the disease. 
Green’s nanoparticles have shown 
the ability to incorporate specifically 
into these BTICs in vivo, opening up 
the possibility of delivering apoptosis 
genes locally during tumour surgery to 
prevent the disease from coming back. 
A related way of manipulating gene 
expression in vivo is RNA interference 
(RNAi), which was similarly greeted with 
high hopes after its discovery in 1998 
but has experienced some setbacks. 
RNAi, which won its discoverers the 
Nobel Prize in 2006, is a supremely 
elegant gene silencing method that 
works like magic in a wide range of 
laboratory systems. However, like 
gene therapy, it experienced trouble in 
the development of suitable delivery 
systems for medical applications. Like 
gene therapy, the RNAi field is now 
looking to nanoparticle solutions for the 
safe delivery of RNA into the targeted 
cells. Daniel Anderson’s group at MIT 
has recently demonstrated successful 
delivery of siRNA to endothelial cells 
in vivo using nanoparticles formed from 
low molecular weight polymers (Nat. 
Nanotechnol. (2014) 9, 648–655).
The MIT spin-out company Alnylam, 
which has survived some serious 
setbacks since its foundation in 2002, 
is now conducting advanced clinical 
trials of an RNAi treatment for familial 
amyloid polyneuropathy (FAP), which 
is expected to reduce the production 
of harmful misfolded protein in the 
patients’ livers by 80%. Further RNA therapies in the company’s pipeline 
include treatments for hemophilia, 
hepatitis B, and high cholesterol levels. 
New disease targets
The initial idea behind gene therapy 
was to replace or repair a single faulty 
gene. This now appears simplistic and 
limiting, as the analyses of the human 
genome have failed to reveal important 
single-gene problems beyond those 
that were known already. Instead, we 
now know that the genetic basis of 
disease is highly complex and involves 
not just gene sequences but also 
regulatory elements in the non-coding 
regions as well as epigenetic markers. 
Even treatments targeting a single 
gene in the traditional sense can have 
a broader benefit, as a recent study 
from the group of Yuji Yamanashi at the 
University of Tokyo has shown (Science 
(2014) 345, 1505–1508). The researchers 
set out repair the gene DOK7 in a mouse 
model of myasthenia, a disease linked 
to a weakness in the neuromuscular 
junction. Introduction of the DOK7 gene 
successfully cured the disease caused 
by a defect in this very gene. 
Beyond that anticipated finding, 
however, the researchers also found 
that the treatment enlarged the 
neuromuscular junction of wild-type 
controls. They hypothesized that 
this effect might also be beneficial in 
animals with unrelated neuromuscular 
disorders, which they could confirm for 
Emery-Dreifuss muscular dystrophy. 
Current Biology Vol 24 No 20
R986
Photo: Courtesy of Bill Kimbel.The benefit could also apply to 
amyotrophic lateral sclerosis (ALS). 
While the mechanism by which the 
gene therapy triggers these beneficial 
effects remains to be elucidated, this 
unexpected finding suggests that 
even gene therapy for rare specific 
gene defects may in some cases have 
broader applicability. 
Recent developments have 
broadened the scope of gene 
therapy beyond the small group of 
simple diseases caused by a single 
gene defect. As outlined above, the 
possibility to introduce apoptosis 
genes into specific cells has opened 
up applications in cancer therapy. The 
company that got the first regulatory 
approval for gene therapy, uniQure, 
also has advanced development 
programmes targeting diseases like 
intermittent porphyria, Sanfilippo B, 
hemophilia B and Parkinson’s disease. 
Surprisingly, even patients with 
infectious diseases can benefit from 
gene therapy. Efforts are underway to 
use a rare gene variant that makes some 
people immune to HIV in the treatment 
of patients who have contracted the 
virus. An initial experimental treatment 
of a patient with leukaemia and HIV 
who received a bone marrow transplant 
from a donor with the resistance gene 
variant suggested that the idea works 
in principle, but that a less invasive 
implementation needs to be found. 
In March this year, researchers 
reported first results of a phase I 
clinical study based on ex vivo gene 
editing to introduce the HIV-resistant 
trait into a population of lymphocytes 
which were then re-injected to the 
patients. While the trial was designed 
only to establish the safety, not the 
efficacy of the treatment, observations 
were encouraging, as several patients 
were able to keep the virus in check 
without their usual daily drugs (N. Engl. 
J. Med. (2014) 370, 901–910). 
The broad range of success stories 
emerging in the last few years has 
given researchers in the field fresh 
optimism, mirrored also in the activity 
of biotech entrepreneurs and venture 
capital firms. In spite of its troubled 
beginnings, it looks like gene therapy 
is now set to take up a significant role 
in clinical practice, fulfilling treatment 
needs that have proven elusive to 
conventional therapies. 
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Why did you initially choose medicine 
as a career? I was hopeless at 
languages — I had a debilitating 
stammer — and in those days you 
learned languages by reading out loud 
from a book and that was beyond 
me. But I was reasonably good at 
science and geography. My method 
for finding a possible career was 
unconventional but practical. My 
parents owned a grocery store. One of 
my chores was to deliver groceries on 
a bicycle. In general, when I delivered 
groceries to the houses of lawyers 
and accountants, I felt my efforts were 
unappreciated. There was, however, 
a medical household where I would 
always be given a glass of lemonade, 
and where my nascent interest in 
medicine was encouraged — Bill Clark 
even gave me his copy of a book of 
essays by Sir William Osler. It is still 
on my bookshelf. His kindness and 
solicitude are why I decided to become 
a doctor.
Why did you switch to 
paleoanthropology? There were 
elements of ‘push’ and ‘pull’: the ‘push’ 
was that I had the good fortune to 
be apprenticed to a surgeon whose 
diagnostic and clinical skills were 
legendary. However, he was so good 
that it was pretty clear to me that, 
no matter hard I worked at it, I was 
unlikely to be as good a surgeon as 
he was. And what was the point of 
doing something like surgery if you 
Q & Acould not be among the best? The 
‘pull’ was my enjoyment of human 
anatomy, combined with the realization 
that because of my good fortune to 
be involved with Richard Leakey’s 
research team, I had the unique 
opportunity to help interpret the new 
evidence they were unearthing.
Why did you choose to work on skulls 
and teeth? I didn’t. I was one of three 
anatomists (the others were Michael 
Day and Alan Walker) Richard Leakey 
had invited to describe and interpret 
the hominin fossils recovered from Lake 
Rudolf. The majority of the fossils were 
from the skull and dentition, but each of 
us wanted to work on the limb bones. 
In 1972, we met in New York to discuss 
the impasse, but none of us would give 
in. So, not a little frustrated, Richard 
broke three matches into different 
lengths and made us draw. Mine was 
the shortest match, so I had no choice 
but to work on the cranial remains. This 
task, which involved determining how 
many taxa were represented among the 
hominin cranial fossils, led to the topic 
of my PhD, sexual dimorphism, and 
my interest in patterns of intra- versus 
interspecific variation. 
What do you enjoy most about being 
a paleoanthropologist? I have a 
passionate dislike of games of chance, 
but I do like solving real-life puzzles. 
All paleontology is challenging, but 
because we are trying to reconstruct 
human evolutionary history on 
